| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | SVP, Chief Medical Officer | Common Stock | 23,280 | $425,212 | $18.27 | 31 Jan 2022 | Direct |
| Nuvalent, Inc. | Director | Class A Common Stock | 5,146 | $343,341 | $66.72 | 18 Jun 2025 | Direct |
| Syndax Pharmaceuticals Inc | SVP, Chief Medical Officer | Stock Options (Right to buy) | 17,350 | $335,723 | $19.35 | 02 Feb 2022 | Direct |
| Nuvalent, Inc. | Director | Stock Option (Right to Buy) | 4,147 | 18 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| NUVL | Nuvalent, Inc. | 18 Jun 2025 | 2 | $0 | 4 | Director | 20 Jun 2025, 16:34 |
| NUVL | Nuvalent, Inc. | 12 Jun 2024 | 2 | $0 | 4 | Director | 14 Jun 2024, 16:10 |
| NUVL | Nuvalent, Inc. | 15 Jun 2023 | 1 | $0 | 4 | Director | 16 Jun 2023, 16:17 |
| NUVL | Nuvalent, Inc. | 04 Oct 2022 | 1 | $0 | 4 | Director | 06 Oct 2022, 16:30 |
| NUVL | Nuvalent, Inc. | 04 Oct 2022 | 0 | $0 | 3 | Director | 06 Oct 2022, 16:25 |
| SNDX | Syndax Pharmaceuticals Inc | 02 Feb 2022 | 2 | +$295,193 | 4 | SVP, Chief Medical Officer | 03 Feb 2022, 16:31 |
| SNDX | Syndax Pharmaceuticals Inc | 30 Dec 2021 | 2 | +$51,743 | 4 | SVP, Chief Medical Officer | 03 Jan 2022, 15:03 |